Pharmaceuticals & Biotech/Lifesciences
FNArena Windows (Sectors)
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
Latest Stories
Michael Gable of Fairmont Equities suggests CSL shares have found a bottom and seem destined for $300-plus yet again
Jul 22 2025
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea is on CSL
Jul 14 2025
| ASX CODE | COMPANY NAME | LAST PRICE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET |
|---|---|---|---|---|---|---|
| ARX | AROA BIOSURGERY LIMITED | $0.56 | $0.82 | $0.35 | 55.7 |
$0.81 |
| AVH | AVITA MEDICAL INC | $1.68 | $4.52 | $1.48 |
$2.70 |
|
| BIO | AVITA MEDICAL INC | $0.52 | $0.87 | $0.39 |
$0.84 |
|
| CSL | CSL LIMITED | $263.95 | $313.25 | $228.61 | 26.0 |
$318.043 |
| CUV | CSL LIMITED | $12.25 | $15.99 | $9.41 |
$19.783 |
|
| GSS | GENETIC SIGNATURES LIMITED | $0.40 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMM | IMMUTEP LIMITED | $0.26 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MAP | MICROBA LIFE SCIENCES LIMITED | $0.10 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MSB | MESOBLAST LIMITED | $2.28 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MVP | MESOBLAST LIMITED | $0.63 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NEU | NEUREN PHARMACEUTICALS LIMITED | $15.75 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NUZ | NEUREN PHARMACEUTICALS LIMITED | $0.16 | $xx.xx | $xx.xx | xx.x | xx.xx |
| OPT | NEUREN PHARMACEUTICALS LIMITED | $0.60 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PAR | NEUREN PHARMACEUTICALS LIMITED | $0.42 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PNV | POLYNOVO LIMITED | $1.24 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PYC | PYC THERAPEUTICS LIMITED | $1.42 | $xx.xx | $xx.xx | xx.x | xx.xx |
| SNT | PYC THERAPEUTICS LIMITED | $0.06 | $xx.xx | $xx.xx | xx.x | xx.xx |
| TLX | TELIX PHARMACEUTICALS LIMITED | $25.12 | $xx.xx | $xx.xx | xx.x | xx.xx |
Previous Stories
The Enigma Surrounding Clinuvel
Jul 03 2025
Clinuvel Pharmaceuticals posted a strong first half result, and offers significant upside in expanding the use of its flagship drug, but investors just aren’t excited
Rudi’s View: CSL & NextDC
May 08 2025
Your Editor attended presentations by CSL and NextDC this week
Behring Margin Outlook Still Main Game For CSL
Feb 13 2025
A weak vaccine result dragged on CSL’s H1 result but analysts focus on an improving plasma product margin and solid growth forecasts in maintaining positive views
Dr Boreham’s Crucible: Arovella Therapeutics
Aug 29 2024
The New Criterion’s Tim Boreham highlights Arovella Therapeutics in a struggling cell therapies sector worldwide
ResMed’s Margin Upside Excites
Aug 07 2024
Sleep treatment leader ResMed has faced a number of headwinds but has surprised analysts with a strong improvement in gross margins
Dr Boreham’s Crucible: Aroa Biosurgery
Jul 29 2024
Tim Boreham revisits the investment case and corporate developments for Aroa Biosurgery
CSL Shares Breaking Free
Jul 23 2024
Michael Gable of Fairmont Equities observes CSL shares are breaking through a ceiling that has held for four years, suggesting major upside potential
Dr Boreham’s Crucible: SDI
Jul 19 2024
The New Criterion’s Tim Boreham shines the light on family-run dental products manufacturer SDI (Formerly Southern Dental Industries)
‘Defensive’ Pharmaceutical Wholesalers In Focus
Jul 18 2024
New research on the Pharmaceutical Wholesaling sector identifies three stocks with long-term defensive growth within an improving government funding framework
Twists And Turns Of Telix And Australian Biotech
Jul 10 2024
In the wake of Telix Pharmaceuticals’ non-IPO on the Nasdaq, FNArena shines a light on the company’s fortunes and that of Australian biotech and cancer research generally
Latest News
| 1 |
The Overnight Report: Trade Deals, New Highs8:38 AM - Daily Market Reports |
| 2 |
Today’s Financial Calendar – 24-07-20258:15 AM - Daily Market Reports |
| 3 |
ASX Winners And Losers Of Today – 23-07-25Jul 23 2025 - Daily Market Reports |
| 4 |
Healthcare’s Challenge: Antimicrobial ResistanceJul 23 2025 - International |
| 5 |
Can Virgin Succeed This Time?Jul 23 2025 - Small Caps |